© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Agreement to Acquire Boehringer
Posted 7th October 2016

Agreement to Acquire Boehringer

Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Agreement to Acquire Boehringer
Image

Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business; subject to FTC approval and closing of BI/Sanofi asset swap

Today Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.’s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for $885 million, including the estimated cost of acquired inventory. The deal will diversify Elanco’s U.S. companion animal portfolio by complementing its offerings for dogs and cats.

Joining Elanco’s U.S. portfolio – which currently includes parasiticides, pain and dermatology medicines – will be routinely administered vaccines for bordetella, Lyme disease, rabies and parvovirus, among others. Also included in the agreement are several pipeline assets.

The Fort Dodge, Iowa-based facility brings capacity to manufacture the acquired products as well as R&D and testing capabilities, including an on-site veterinary research center and lab space.

“We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives,” said Jeff Simmons, president, Elanco Animal Health. “With a growing portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet caregivers to do just that.”

The acquisition is anticipated to close by early 2017, subject to approval by the Federal Trade Commission and also subject to antitrust approval and closing of Boehringer Ingelheim’s asset swap transaction with Sanofi.

The sale of BIVI’s U.S. pet vaccines business and Fort Dodge manufacturing site is a required step toward the acquisition of Merial by Boehringer Ingelheim.

The current vaccine portfolio to be acquired has experienced revenue growth over the past three years, and Lilly expects the acquisition to be accretive to GAAP earnings in 2019 and to non-GAAP earnings in 2018.

John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer, said that the planned acquisition of BIVI’s U.S. feline, canine and rabies vaccines portfolio reaffirms Lilly’s confidence in Elanco’s growth potential.

“As a result of the acquisition, Elanco will bring greater value to customers by providing a suite of options for preventing common diseases in companion animals,” said Lechleiter. “Coupled with our robust food animal portfolio, this addition further strengthens Elanco’s position in the global animal health business.”

Jefferies LLC is acting as the exclusive financial advisor and Paul Hastings LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as legal advisors to Elanco and Lilly in this transaction.

Categories: M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
CEO of the Month: USA
Innovation
29/06/2016CEO of the Month: USA

OCEANWORX is a global sports marketing, media production and distribution founded by international media authority David Jones in the year 2000

Read Full PostRead - Eye Icon
Suing a Hospital for Malpractice: A Guide
News
29/08/2023Suing a Hospital for Malpractice: A Guide

A core principle of any kind of medical practice is to safeguard patient well-being. Sadly, it’s not rare to find instances of medical malpractice and negligence. When medical care falls short of accepted standards in any way, the patient has the right t

Read Full PostRead - Eye Icon
Healthcare Heroes
Innovation
04/01/2021Healthcare Heroes

Did you know that every three minutes, a traveller needs emergency medical treatment abroad? For those people in need of urgent assistance, the team at Angels of Flight Canada Inc. are a godsend, providing expert medical advice in a challenging situation. Earn

Read Full PostRead - Eye Icon
3 Proven Strategies for Mastering the Art of Closing High-Stake M&A Deals
M&A
31/05/20233 Proven Strategies for Mastering the Art of Closing High-Stake M&A Deals

Mergers and acquisitions have always been risky undertakings that can end without profit. The most complex transactions can rightfully involve M&A that can drag on for years without any visible results.

Read Full PostRead - Eye Icon
Experts in the IP Field
Strategy
01/11/2016Experts in the IP Field

Am Badar & Partners is one of the leading intellectual property (IP) firms in Indonesia.

Read Full PostRead - Eye Icon
Innovate to Improve
Innovation
15/01/2020Innovate to Improve

Ensuring that safety procedures are completely and totally compliant with all the necessary rules and regulations is becoming increasingly important with more guidelines coming into effect every year. One firm, The Compliance Workbook (TCW), are helping client

Read Full PostRead - Eye Icon
Christmas cancelled for nearly half of SMEs
Leadership
18/12/2015Christmas cancelled for nearly half of SMEs

Zurich’s latest SME Risk Index reveals nearly half (49%) of SME decision makers have worked on Christmas Day.

Read Full PostRead - Eye Icon
The Italian  Artificial Intelligence Startup Factory: Creating Startups Through Innovation
Innovation
29/07/2022The Italian Artificial Intelligence Startup Factory: Creating Startups Through Innovation

Established in 2020 ago in Milan, Italy, FoolFarm Spa has been recognised as the Leading Artificial Intelligence Venture Builder and is the leading European venture studio in the AI blockchain and cybersecurity sectors.

Read Full PostRead - Eye Icon
2016 Intellectual Property Practitioner of the Year – Peru
Legal
31/07/20162016 Intellectual Property Practitioner of the Year – Peru

Over the years, Estudio Colmenares & Associados has grown to becoming the IP firm of choice in our region of Peru. Although there are a number of reasons why this is the case, we believe that our experience is what separates us form any of our competitors.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow